ReviewDrugs1997
Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.
Review in Drugs, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04209192 (Randomized Phase II Study of Antibiotic Prophylaxis With Fosfomycin vs Amikacin in Transurethral Resection of Bladder), which is not on this map. Cited by 85 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Phase II Study of Antibiotic Prophylaxis With Fosfomycin vs Amikacin in Transurethral Resection of Bladder
Who cites it
85 citing papers in PubMed, 4 syntheses or guidelines pooled it, 272 citations in OpenAlex.
- Comparing fosfomycin and ciprofloxacin for uncomplicated UTI treatment in adults: better bacterial eradication but non-significant clinical remission-a systematic review and meta-analysis.International urology and nephrology · 2025Pooled it
- Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis.International urogynecology journal · 2022Pooled it
- Fosfomycin in continuous or prolonged infusion for systemic bacterial infections: a systematic review of its dosing regimen proposal from in vitro, in vivo and clinical studies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Pooled it
- Treatments for symptomatic urinary tract infections during pregnancy.The Cochrane database of systematic reviews · 2011Pooled it
- Population pharmacokinetics of oral fosfomycin calcium in healthy women.The Journal of antimicrobial chemotherapy · 2024Trial
- Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Trial
- Antibacterial effect of fosfomycin tromethamine on the bacteria inside urinary infection stones.International urology and nephrology · 2020Trial
- Evaluation of perioperative prophylaxis with fosfomycin tromethamine in ureteroscopic stone removal: an investigator-driven prospective, multicenter, randomized, controlled study.International urology and nephrology · 2018Trial
- Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2009Trial
- Penetration of fosfomycin into inflammatory lesions in patients with cellulitis or diabetic foot syndrome.Antimicrobial agents and chemotherapy · 2003Trial
- Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues.Antimicrobial agents and chemotherapy · 2000Trial
- A microphysiological human mini-bladder reveals urine-urothelium interplay in tissue resilience and UPEC recurrence in urinary tract infections.Nature communications · 2026Article
- Neurotoxicity of Broad-Spectrum Antibiotics in Urinary Tract Infections: Mechanisms and Clinical Implications.Advances in urology · 2026Review
- Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections.Scientific reports · 2025Article
- Population pharmacokinetics of intravenous fosfomycin: dose optimization for critically ill patients with and without kidney replacement therapy.Antimicrobial agents and chemotherapy · 2025Observational
- Novel Fosfomycin Resistance Mechanism inAntibiotics (Basel, Switzerland) · 2024Article
- The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review.Indian journal of microbiology · 2024Review
- Fosfomycin-induced liver injury: A case report and literature review.Canadian liver journal · 2024Article
- Comparison of genotypic and phenotypic antimicrobial resistance profiles ofJournal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc · 2024Article
- Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study.Antibiotics (Basel, Switzerland) · 2024Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin tromethamine is a phosphonic acid bactericidal agent with in vitro activity against most urinary tract pathogens. It is particularly active against Escherichia coli, and Citrobacter, Enterobacter, Klebsiella, Serratia and Enterococcus spp. There appears to be little cross-resistance between fosfomycin and other antibacterial agents, possibly because it differs from other agents in its general chemical structure and site of action. In its new formulation as the oral tromethamine salt, fosfomycin has 34 to 41% oral bioavailability, has a mean elimination half-life of 5.7 hours, and is primarily excreted unchanged in the urine. Following a single 3 g oral dose, peak urinary concentrations occur within 4 hours and remain high (> 128 mg/L) for 24 to 48 hours, which is sufficient to inhibit most urinary tract pathogens. In clinical trials in patients with acute uncomplicated lower urinary tract infection, single-dose fosfomycin tromethamine therapy was effective, and comparable with several other antibacterial agents given either as single-dose or multiple-dose treatments [e.g. beta-lactam and fluoroquinolone agents, cotrimoxazole (trimethoprim-sulfamethoxazole), nitrofurantoin and pipemidic acid]. Bacteriological eradication rates of 75 to 90% were achieved 5 to 11 days after therapy, with eradication rates of 62 to 93% 4 to 6 weeks after therapy. In 3 large double-blind comparisons with ciprofloxacin, cotrimoxazole and nitrofurantoin, 99% of fosfomycin tromethamine recipients and 100% of patients receiving comparator agents were considered clinically cured or improved after therapy. Fosfomycin tromethamine is well tolerated, with a low incidence of adverse events. These comprise mainly gastrointestinal symptoms that are transient, mild and self-limiting. Thus, fosfomycin tromethamine achieves high clinical and bacteriological cure rates in patients with acute uncomplicated lower urinary tract infection and is well tolerated. The single-dose administration regimen and favourable US pregnancy category rating of fosfomycin tromethamine should also encourage its use in this indication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.